Trial Profile
A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2023
Price :
$35
*
At a glance
- Drugs Rovaleucel (Primary) ; Carboplatin; Gemcitabine
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Registrational; Therapeutic Use
- Acronyms VANCE
- Sponsors Tessa Therapeutics
- 19 Oct 2022 Status changed from active, no longer recruiting to completed.
- 05 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Jan 2023.
- 01 Mar 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Feb 2021.